Along these lines of thinking, the enrichment of TEMs that we observed in the proximity of human CRC liver metastases suggests that these cells, once properly engineered, are best positioned to target effective IFNα doses to cancer sites. The gene discussed is IFNA1; the disease is colorectal carcinoma.